Bridging the divide between discovery and delivering patient-specific medicines is the goal of many biotech companies. Our unique approach utilises Tay Therapeutics’ technology platforms coupled to in-house discovery and development expertise to deliver substantial improvements in patient care.

Squiggle Graphic
May 1, 2023
Tay Therapeutics Announces Licensing to VYNE Therapeutics of Oral BET Inhibitor for immuno-inflammatory and fibrotic disorders
April 19, 2023
VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis
March 30, 2023
VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201